North America

Thu
02
May

Scotts Miracle-Gro jumps most in decade on pot-supplies rebound

Scotts Miracle-Gro Co. (SMG.N) rose the most in a decade after its Roundup herbicide and marijuana-supplies business rebounded from sales slumps, boosting earnings above expectations.

Increased advertising to help counter the negative publicity generated by concerns about Roundup’s safety contributed to a 20 per cent rise in quarterly sales of the weedkiller, Chief Executive Officer Jim Hagedorn said on a conference call with analysts Wednesday to discuss results.

Meanwhile, a burgeoning black market for cannabis in California reversed the effects of a regulatory crackdown last year. Revenue benefited from higher profit margins to illicit growers, said Chris Hagedorn, the CEO’s son and general manager of the pot-supplies business.

Thu
02
May

Curaleaf bets $1.27 billion on cannabis oil in largest U.S. deal

Curaleaf Holdings Inc., the most valuable U.S. marijuana company, is making a big bet on cannabis oil.

The Massachusetts-based company is buying the regulated cannabis business of Cura Partners Inc., a maker of oil for vape pens, in a stock deal valued at about $1.27 billion (US$950 million). That makes it the largest acquisition so far between U.S. cannabis companies. Cura, based in Portland, Oregon, sells its Select brand marijuana products in more than 900 dispensaries, including in California, which is home to the world’s largest legal weed market. It had revenue of about US$117 million last year.

Acquiring Select gives Curaleaf a popular West Coast brand it can sell at its dispensaries around the U.S., according Boris Jordan, the company’s chairman.

Thu
02
May

Marijuana: A $166 billion market?

Marijuana may be "just a plant," but it has Wall Street and investors seeing green and grinning ear to ear at its long-term growth potential.

Long considered a taboo topic, cannabis has forced its way into the mainstream. In the United States, where favorability toward broad-based legalization stood at just 25% in 1995, an all-time record number of people (66%) now want to see marijuana legalized nationally. This growing support is a big reason why there are now 33 states that have given medical cannabis the green light, and 10 of those states have also given the OK to recreational pot.

Thu
02
May

Research begins to develop medical cannabis suppositories for patients suffering from IBD

Panaxia Pharmaceutical Industries Israel and the pharmaceutical company Rafa, announced the signing of a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company in a recent press release.

Thu
02
May

New funding for cannabis research offers MS patients hope for the future

When Jessica Turner was diagnosed with multiple sclerosis (MS) at age 31, she didn’t want to talk about it—and she didn’t want to take drugs.

“I wasn’t ready to accept that this was happening to me,” Turner tells The GrowthOp. She also didn’t want to accept experiencing the flu-like symptoms that so often accompany interferons, the oldest and most prescribed drug options for patients with relapsing-remitting MS.

Wed
01
May

Cannabis stocks can be a lucrative — but risky — bet

Cannabis stocks aren't just another market fad. They can be a solid long-term bet — as long as you're careful.

Wed
01
May

New study: CBD diminishes THC-related impairment

In a new study from the University College London (UCL), a team of researchers focused on the difference between consuming cannabis strains that have high levels of THC, and strains that have significant quantities of both THC and CBD.

The precise effects on the brain were monitored by an fMRI (functional magnetic resonance imaging), which measures changes in blood flow and neural activity.

Brain scans of the 17 participants showed that the high-THC strain impaired the functionality of the default mode network, especially in the posterior cingulate area.

Wed
01
May

How cannabis microdosing can be used for pain management

Medical cannabis is currently legal in 29 states. Of those, none provide insurance coverage for the substance. This leaves consumers in a difficult situation: choose to purchase cannabis at their own expense or choose a potentially more harmful or addictive pharmaceutical medication covered by insurance. The dilemma is not new, but consumers and entrepreneurs alike are creating inventive ways to deal with the problem.

Wed
01
May

Moosehead enters cannabis drink market with Sproutly joint venture

Moosehead Breweries Ltd., one of Canada’s largest brewers, is getting into the cannabis business.

The Saint John, N.B.-based brewer announced it plans to form a joint venture with Sproutly Canada Inc., a cannabis producer and extractor, to develop pot-infused beverages that will be released later this year in the Canadian market.

“With the anticipated legalization of edibles in Canada later this year, Moosehead has made the strategic decision to enter the cannabis beverage market,” said Andrew Oland, CEO of Moosehead, in a release. “As one of the oldest brands in Canada and a leader in the beer category, we believe we are uniquely positioned to be a leader in the cannabis beverage category.”

Wed
01
May

Treating complex post-traumatic stress disorder (C-PTSD) with medical cannabis

“I’ve got to treat my body if I’m ever going to recover from this illness,” Kimberly Callis, an independent researcher with Complex Post-Traumatic Stress Disorder, tells High Times. “Cannabis [is] a systemic medicine; complex PTSD is a systemic condition. The two really go hand-in-hand, especially with a target on the endocannabinoid system.”

Pages

Subscribe to RSS - North America